摘要
目的:探讨结缔组织生长因子(connective tissue growth factor,CTGF)在卵巢癌组织中的表达及临床意义。方法:采用免疫组化和逆转录聚合酶链反应(RT-PCR)方法检测105例卵巢癌、20例正常卵巢组织和30例良性卵巢肿瘤组织中CTGF的表达,并分析CTGF与卵巢癌临床病理参数的关系。结果:免疫组化检测观察到CTGF主要定位于细胞质内,卵巢癌、正常卵巢组织和良性卵巢肿瘤中CTGF的阳性表达率分别为53.33%(56/105)、95.00%(19/20)、93.33%(28/30),卵巢癌中CTGF阳性表达率低于正常卵巢(χ^2=12.15,P=0.00)及良性卵巢肿瘤组织(χ^2=15.88,P=0.00),正常卵巢与良性卵巢肿瘤组织相比较差异无统计学意义(χ^2=0.05,P=0.80),RT-PCR检测结果显示卵巢癌中CTGF mRNA的表达明显低于正常卵巢组织和良性卵巢肿瘤组织(F=3.39,P=0.039)。进一步采用χ^2检验统计分析得出CTGF与卵巢癌的临床分期、淋巴转移相关(P〈0.05),而与年龄、病理分级、病理类型及腹水癌细胞阳性率无相关性(P〉0.05)。结论:CTGF在卵巢癌中低表达,与卵巢癌的发生、发展相关。
Objective:To investigate the expression and clinical significance of connective tissue growth factor (CTGF) in ovarian cancer. Methods: The expression levels of CTGF in 20 cases of normal ovarian tissues,30 cases of benign ovanan tumor tissues and 105 cases of ovarian cancer tissues were examined by RT-PCR and immunohistochemical staining, and the correlation between CTGF expression and clinicopathological significance of ovarian cancer was analyzed. Results: The posi- tive rate of CTGF expression in normal ovarian tissues, benign ovarian tumor tissues and ovarian cancer tissues were 95.00% (19/20) ,93.33% (28/30) and 53.33% (56/105)respectively; the positive rate of CTGF in ovarian cancer tissues was sig- nificantly lower than that of normal ovarian tissues(χ2 = 12. 15, P =0.00) and benign ovarian tumor tissues(χ2 = 15.88, P = 0.00) ; there was no significant difference in the positive rate between normal ovarian tissues and benign ovarian tumor tissues(χ2 = 15.88, P =0.00). The CTGF mRNA expression in ovarian cancer tissue was lower than that in normal ovarian tissue and benign ovarian tumor tissue showed by RT-PCR ( F = 3.39 ,P =0. 039). Data was processed by χ2 analysis, and the results showed that the expression of CTGF was correlated with clinical stages, lymph node metastasis ( P 〈 0. 05 ), but not correlated with age, pathologic type,pathologic grade and positive rate of ascites tumor cells (P 〉 0.05 ). Conclusion: CTGF was low expressed in overian cancer tissues and correlate with the occurrence and progression of ovarian cancer.
出处
《中国肿瘤生物治疗杂志》
CAS
CSCD
北大核心
2016年第1期102-105,共4页
Chinese Journal of Cancer Biotherapy
基金
青岛市公共领域科技支撑计划资助项目(No.13-1-3-62-nsh)~~